Table 1.

Correlation between BCL3 expression and clinical parameters of 100 AML patients

Patients’ parameters	BCL3 expression
	Low (n = 50)	High (n = 50)	P value
Sex, male/female	33/16	25/26	0.063
Median age, month, (range)	91.67 (9–149)	78 (7–166)	0.215
Median WBC, ×109/L (range)	15.5 (0.42–275.9)	16.9 (1.05–300.55)	0.811
Median HGB, g/L (range)	75 (20–111)	77.67 (1.96–108)	0.947
Median PLT,×109/L, (range)	41 (10–179)	66.33 (10–586)	0.017
BM blasts, % (range),	63 (15–95)	72.5 (12–98)	0.699
PB blasts, % (range)	56.8 (2–91)	41.33 (2–94)	0.201
FAB classification	n = 47	n = 50
M1	1 (1%)	3 (3.1%)	0.338
M2	30 (30.9%)	18 (18.6%)	0.006
M4	7 (7.2%)	13 (13.4%)	0.177
M5	9 (9.3%)	13 (13.4%)	0.420
M4 + M5	16	26	0.064
M6	0 (0%)	1 (1%)	0.330
M7	0 (0%)	2 (2.1%)	0.166
Karyotypes	n = 50	n = 50
Normal	4 (4%)	15 (15%)	0.0059
t(8;21)	23 (23%)	10 (10%)	0.0047
Inv(16)	5 (5%)	8 (8%)	0.3936
+ 8	0 (0%)	1 (1%)	0.3197
-5/5q	1 (1%)	0 (0%)	0.3101
-7/7q	0 (0%)	1 (1%)	0.3197
MLL rearrangement	4 (4%)	7 (7%)	0.3558
Complex	4 (4%)	2 (2%)	0.3860
Other	5 (5%)	4 (4%)	0.7037
No data	4 (4%)	3 (2%)	0.6752
Karyotype classification	n = 46	n = 51	0.278
Favorable	18	17
Intermediate	24	22
Unfavorable	7/	12
Gene mutation	n = 49	n = 51
No mutation (± )	14	8	0.1339
C-Kit (± )	9	2	0.0232
FLT3-ITD (± )	1	5	0.0486
CEBPA	0	2	0.1573
NPM1	1	0	0.3101
No data	24	34	0.0893
CR
CR1 (CR/PR/NR)	30/12/7	22/21/8	0.156
CR2 (CR/PR/NR)	36/5/8	36/9/6	0.499

AML, acute myeloid leukemia; WB, white blood cells; HB, hemoglobin; PLT, Platelet; BM, bone marrow; PB, peripheral blood; FAB, French-American-British; CR, complete remission; PR, partial remission; NR, no remission